NASDAQ:MDVXU - Medovex Stock Price, News, & Analysis

Sign in or create an account to add this stock to your watchlist.
Previous Close$5.84
Today's Range$5.75 - $6.75
52-Week Range$5.75 - $6.75
Volume880,077 shs
Average VolumeN/A
Market CapitalizationN/A
P/E RatioN/A
Dividend YieldN/A
Medovex Corp. is a development-stage company. The Company focuses on obtaining, developing and commercializing various intellectual property rights (patents, patent applications and knowhow) in the medical technology area, with particular focus on the development of medical devices. It focuses on development and commercialization of the DenerveX System, which consists of the DenerveX Device and the DenerveX Pro-40 power generator (DenerveX). DenerveX is a device that is intended to be used in the treatment of conditions resulting from the degeneration of joints in the spine that cause back pain. The DenerveX Pro-40 Power Generator is the power source for the DenerveX System. The system works in synchronization to deliver controlled and precise therapy to patients with facet joint pain. DenerveX combines two procedures in one: capsular tissue removal through a light tissue scraping action and radio ablation denervation. DenerveX is commercially not available in the United States.

Receive MDVXU News and Ratings via Email

Sign-up to receive the latest news and ratings for MDVXU and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry N/A
Current SymbolNASDAQ:MDVXU



Sales & Book Value

Annual SalesN/A



OptionableNot Optionable

Medovex (NASDAQ:MDVXU) Frequently Asked Questions

What is Medovex's stock symbol?

Medovex trades on the NASDAQ under the ticker symbol "MDVXU."

Has Medovex been receiving favorable news coverage?

Media stories about MDVXU stock have been trending positive this week, according to InfoTrie Sentiment Analysis. The research group identifies positive and negative news coverage by reviewing more than six thousand news and blog sources. The firm ranks coverage of companies on a scale of negative five to positive five, with scores closest to five being the most favorable. Medovex earned a media sentiment score of 2.7 on InfoTrie's scale. They also assigned news articles about the company a news buzz of 6.0 out of 10, meaning that recent news coverage is somewhat likely to have an effect on the stock's share price in the next few days.

Who are Medovex's key executives?

Medovex's management team includes the folowing people:
  • Jesse Crowne, Executive Co-Chairman of the Board (Age 33)
  • Larry W. Papasan, Co-Chairman of the Board (Age 77)
  • Patrick Kullmann, President (Age 61)
  • Jarrett Gorlin, Chief Executive Officer, Director (Age 40)
  • Charles Duane Farrahar, Chief Financial Officer, Company Secretary (Age 56)
  • Dennis Moon, Senior Vice President (Age 41)
  • James R. Andrews M.D., Director (Age 74)
  • Randal R. Betz M.D., Director (Age 59)
  • Ron Lawson, Director (Age 72)
  • Jon Mogford Ph.D., Director (Age 49)

When did Medovex IPO?

(MDVXU) raised $8 million in an IPO on Friday, December 19th 2014. The company issued 1,400,000 shares at $5.75 per share. Laidlaw & Company (UK) Ltd. acted as the underwriter for the IPO.

How do I buy shares of Medovex?

Shares of MDVXU can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Medovex's official website?

The official website for Medovex is

How can I contact Medovex?

Medovex's mailing address is 3060 Royal Blvd S Ste 150, ALPHARETTA, GA 30022-1418, United States. The company can be reached via phone at +1-404-3936989.

MarketBeat Community Rating for Medovex (NASDAQ MDVXU)

Community Ranking:  2.5 out of 5 (star star half star)
Outperform Votes:  50 (Vote Outperform)
Underperform Votes:  50 (Vote Underperform)
Total Votes:  100
MarketBeat's community ratings are surveys of what our community members think about Medovex and other stocks. Vote "Outperform" if you believe MDVXU will outperform the S&P 500 over the long term. Vote "Underperform" if you believe MDVXU will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 2/20/2019 by Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with's FREE daily email newsletter.

Yahoo Gemini Pixel